{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:58:13Z","timestamp":1789595893010,"version":"build-2803163510"},"reference-count":44,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patients. Height, weight, disease activity scores, lipid profile and atherogenic indices (AI), leptin, adiponectin, resistin, interleukin-6, and high-sensitivity C-reactive protein (CRP) were measured before and four months after initiation of TCZ in 40 RA patients and 40 healthy controls. Following TCZ treatment, total cholesterol, high density lipoprotein (HDL), and triglycerides were significantly elevated, but no significant changes in weight, body mass index (BMI), low density lipoprotein (LDL), and AI were observed. Compared with controls, significantly higher adiponectin levels were measured in the RA group at baseline. Following TCZ treatment, resistin levels and the leptin-to-adiponectin ratio increased, adiponectin levels decreased, and leptin levels remained unchanged. No correlation was found between the change in adipokine serum levels and changes in the disease activity indices, nor the lipid profile. In conclusion, the changes observed suggest a protective role for TCZ on the metabolic and cardiovascular burden associated with RA, but does not provide a mechanistic explanation for this phenomenon.<\/jats:p>","DOI":"10.3390\/ijms20184633","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T11:01:15Z","timestamp":1568804475000},"page":"4633","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis"],"prefix":"10.3390","volume":"20","author":[{"given":"Elinoar","family":"Hoffman","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Carmel Medical Center, Haifa 3436212, Israel"},{"name":"The Immunotherapy Laboratory, Carmel Medical Center, Haifa 3436212, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3109601, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal A.","family":"Rahat","sequence":"additional","affiliation":[{"name":"The Immunotherapy Laboratory, Carmel Medical Center, Haifa 3436212, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3109601, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Feld","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Carmel Medical Center, Haifa 3436212, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Elias","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Carmel Medical Center, Haifa 3436212, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzhak","family":"Rosner","sequence":"additional","affiliation":[{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3109601, Israel"},{"name":"Rheumatology Unit, Bnai Zion Medical Center, Haifa, 3339419, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kaly","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Bnai Zion Medical Center, Haifa, 3339419, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idit","family":"Lavie","sequence":"additional","affiliation":[{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3109601, Israel"},{"name":"Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa 3436212, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8612-2698","authenticated-orcid":false,"given":"Tal","family":"Gazitt","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Carmel Medical Center, Haifa 3436212, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-2292","authenticated-orcid":false,"given":"Devy","family":"Zisman","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Carmel Medical Center, Haifa 3436212, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3109601, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1016\/j.ijcard.2013.07.113","article-title":"High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy","volume":"168","author":"Koenig","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","article-title":"Explaining How \u201cHigh-Grade\u201d Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/acr.20488","article-title":"Cardiometabolic comorbidities and rheumatic diseases: Focus on the role of fat mass and adipokines","volume":"63","author":"Lago","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.atherosclerosis.2007.01.004","article-title":"Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis","volume":"196","author":"Chung","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/1756-185X.12999","article-title":"New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis","volume":"20","author":"Mahmoudi","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/ard.2005.046540","article-title":"Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis","volume":"65","author":"Otero","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"343746","DOI":"10.1155\/2014\/343746","article-title":"Adipokines, Metabolic Syndrome and Rheumatic Diseases","volume":"2014","author":"Abella","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bcp.2019.03.030","article-title":"Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases","volume":"165","author":"Francisco","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_9","first-page":"425068","article-title":"Adipokines as Potential Biomarkers in Rheumatoid Arthritis","volume":"2014","author":"Salvi","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11845-014-1072-9","article-title":"Increased leptin levels in patients with rheumatoid arthritis: A meta-analysis","volume":"183","author":"Tian","year":"2014","journal-title":"Ir. J. Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1100\/2011\/290142","article-title":"Beyond fat mass: Exploring the role of adipokines in rheumatic diseases","volume":"11","author":"Scotece","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/cei.12372","article-title":"Emerging role of leptin in rheumatoid arthritis","volume":"177","author":"Tian","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fimmu.2013.00453","article-title":"CBT-506 Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study","volume":"4","author":"Toussirot","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/BF03346639","article-title":"Adiponectin-leptin ratio: A useful estimate of insulin resistance in patients with Type 2 diabetes","volume":"33","author":"Zaletel","year":"2010","journal-title":"J. Endocrinol. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00125-009-1508-3","article-title":"Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals","volume":"52","author":"Finucane","year":"2009","journal-title":"Diabetologia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R194","DOI":"10.1186\/ar4384","article-title":"Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis","volume":"15","author":"Kang","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10067-015-3106-8","article-title":"Insulin resistance and levels of adipokines in patients with untreated early rheumatoid arthritis","volume":"35","author":"Valdivielso","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_18","unstructured":"Jameson, J.L., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Loscalzo, J. (2012). Rheumatoid Arthritis. Harrison\u2019s Principles of Internal Medicine, McGraw-Hill."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00296-009-1303-y","article-title":"Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis","volume":"31","author":"Kawashiri","year":"2011","journal-title":"Rheumatol. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_22","unstructured":"Central Bureau of Statistics (2012). Israel in Comparison with the OECD Countries & the EU."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Schultz, O., Oberhauser, F., Saech, J., Rubbert-Roth, A., Hahn, M., Krone, W., and Laudes, M. (2010). Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014328"},{"key":"ref_24","first-page":"293","article-title":"Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: Potential cardiovascular protective role of IL-6 inhibition","volume":"37","author":"Fioravanti","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10067-016-3183-3","article-title":"Body mass index and response to tocilizumab in rheumatoid arthritis: A real life study","volume":"35","author":"Gardette","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cyto.2012.11.007","article-title":"Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-\u03b1 in patients with inflammatory rheumatic disorders: A 16-week comparative study","volume":"61","author":"Younis","year":"2013","journal-title":"Cytokine"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ando, K., Takahashi, F., Kato, M., Kaneko, N., Doi, T., Ohe, Y., Koizumi, F., Nishio, K., and Takahashi, K. (2014). Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0102436"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"785946","DOI":"10.1155\/2012\/785946","article-title":"Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: The impact of therapy with biologicals","volume":"2012","author":"Popa","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"ref_29","first-page":"240","article-title":"Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease","volume":"29","author":"Niroumand","year":"2015","journal-title":"Med. J. Islam. Repub. Iran."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/DDDT.S41437","article-title":"Tocilizumab in the treatment of rheumatoid arthritis and beyond","volume":"8","author":"Sweiss","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8410182","DOI":"10.1155\/2018\/8410182","article-title":"Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities","volume":"2018","author":"Ruscitti","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","article-title":"Cardiovascular risk in rheumatoid arthritis: Recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment","volume":"53","author":"Choy","year":"2014","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mac Donald, I.J., Liu, S.C., Huang, C.C., Kuo, S.J., Tsai, C.H., and Tang, C.H. (2019). Associations between adipokines in arthritic disease and implications for obesity. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061505"},{"key":"ref_34","first-page":"471","article-title":"Leptin and adiponectin as predictors of disease activity in rheumatoid arthritis","volume":"33","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jcsm.12189","article-title":"Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis","volume":"8","author":"Tournadre","year":"2017","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"ref_36","first-page":"311","article-title":"Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis","volume":"26","author":"Martin","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_37","first-page":"596","article-title":"High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis","volume":"26","author":"Llorca","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_38","first-page":"222","article-title":"Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis","volume":"27","author":"Berja","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12291-011-0119-1","article-title":"Correlation of adiponectin and leptin with insulin resistance: A pilot study in healthy North Indian population","volume":"26","author":"Yadav","year":"2011","journal-title":"Indian J. Clin. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/rheumatology\/33.8.707","article-title":"Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis","volume":"33","author":"Jones","year":"1994","journal-title":"Br. J. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"vi21","DOI":"10.1093\/rheumatology\/kes282","article-title":"Rheumatoid arthritis disease measurement: A new old idea","volume":"51","author":"Hobbs","year":"2012","journal-title":"Rheumatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The Disease Activity Score and the EULAR Response Criteria","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"ref_44","first-page":"S65","article-title":"The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis","volume":"32","author":"Renskers","year":"2016","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/18\/4633\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:21:35Z","timestamp":1760188895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/18\/4633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":44,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["ijms20184633"],"URL":"https:\/\/doi.org\/10.3390\/ijms20184633","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]}}}